Biotech Values

[DewDiligence]

PBM consolidation will boost payers’ leverage (duh):

http://www.bloomberg.com/news/articles/2015-03-30/insurer-fight-on-pricey-drugs-to-intensify-after-catamaran-deal

Once UnitedHealth’s $12.8 billion acquisition closes, 75% of prescriptions filled in the U.S. will be in the hands of three players.

OptumRx, UnitedHealth’s drug benefit arm, covers about 30 million people, while Catamaran represents about 35 million. [I.e. the merged UNH-VTRX will cover 65M lives.] That compares with about 90 million people for Express Scripts and more than 65 million for CVS.